Previous 10 | Next 10 |
Abiomed (NASDAQ:ABMD) will highlight the benefits of complete revascularization with Protected PCI and the value of Impella protocol-based treatment for survival and native heart recovery in cardiogenic shock patients at the 31 st Transcatheter Cardiovascular Therapeutics (TCT) conference ...
The global trade war is in full swing and economists are increasingly worried about the possibility of the U.S. entering a recession. What's an investor to do? One answer is to buy stocks from industries that are naturally recession-resistant, such as the healthcare industry . But which ...
Abiomed (NASDAQ: ABMD) stock plummeted 30.7% in August, according to data from S&P Global Market Intelligence . Shares of the Massachusetts-based maker of minimally invasive heart pumps are down 41.7% in 2019 through Sept. 6. The healthcare stock remains a big winner, howev...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Abiomed's ( ABMD ) stock has seen a steady decline since last September. Back then, the stock was trading at its all-time high around $460. Even though the company had taken a beating, I expected the latest earnings to help it rebound. That didn't happen though. The numbers were impressive, in...
Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019 at 9:55am EDT....
Survival of the fittest. It applies in the wild, and it applies in the business world. The companies that survive and thrive must possess something that others don't. Pretty much every company will say that it has competitive advantages over rivals. Although those advantages aren't always all t...
Inogen (NASDAQ: INGN) and Abiomed (NASDAQ: ABMD) are innovative medical device companies that have put up impressive growth numbers in recent years. However, they both failed to meet Wall Street's expectations for their second-quarter earnings results and cut full-year guidance in respon...
On this week's episode of Industry Focus: Healthcare , host Shannon Jones and Motley Fool contributor Brian Feroldi catch listeners up on four companies we've talked about before: Abiomed (NASDAQ: ABMD) , Inogen (NASDAQ: INGN) , Guardant Health (NASDAQ: GH) , and Shoc...
News, Short Squeeze, Breakout and More Instantly...
Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support...
Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400 PR Newswire NEW YORK , Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent...
Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’s newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have...